These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Long-term benefits of inhaled tobramycin in children with cystic fibrosis: first clinical observations from Poland. Stelmach I; Korzeniewska A; Stelmach W Respiration; 2008; 75(2):178-81. PubMed ID: 17435382 [TBL] [Abstract][Full Text] [Related]
3. TOBI Podhaler for cystic fibrosis patients with Pseudomonas aeruginosa. Farinde A Nurse Pract; 2015 Jul; 40(7):16-7. PubMed ID: 26080292 [No Abstract] [Full Text] [Related]
4. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Cheer SM; Waugh J; Noble S Drugs; 2003; 63(22):2501-20. PubMed ID: 14609360 [TBL] [Abstract][Full Text] [Related]
6. [Use of inhaled tobramycin in patients with cystic fibrosis]. Chermenskiĭ AG; Gembitskaia TE Ter Arkh; 2010; 82(8):76-8. PubMed ID: 20873251 [TBL] [Abstract][Full Text] [Related]
7. Tobramycin and carbenicillin compared with gentamicin and carbenicillin in the treatment of infection with Pseudomonas aeruginosa in adult patients with cystic fibrosis. Hodson ME; Wingfield HJ; Batten JC Br J Dis Chest; 1983 Jan; 77(1):71-7. PubMed ID: 6407508 [TBL] [Abstract][Full Text] [Related]
8. [TOBI Podhaler for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis patients]. Pierart F Rev Med Liege; 2013 Sep; 68(9):486-8. PubMed ID: 24180205 [TBL] [Abstract][Full Text] [Related]
9. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients. Cantón R; Cobos N; de Gracia J; Baquero F; Honorato J; Gartner S; Alvarez A; Salcedo A; Oliver A; García-Quetglas E; Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983 [TBL] [Abstract][Full Text] [Related]
10. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. Burns JL; Van Dalfsen JM; Shawar RM; Otto KL; Garber RL; Quan JM; Montgomery AB; Albers GM; Ramsey BW; Smith AL J Infect Dis; 1999 May; 179(5):1190-6. PubMed ID: 10191222 [TBL] [Abstract][Full Text] [Related]
11. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Hazinski TA J Pediatr; 1999 Jul; 135(1):130. PubMed ID: 10428654 [No Abstract] [Full Text] [Related]
12. Long-term tobramycin aerosol therapy of chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis. Gappa M; Steinkamp G; Tümmler B; von der Hardt H Scand J Gastroenterol Suppl; 1988; 143():74-6. PubMed ID: 3164515 [TBL] [Abstract][Full Text] [Related]
13. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review. Ratjen F; Brockhaus F; Angyalosi G J Cyst Fibros; 2009 Dec; 8(6):361-9. PubMed ID: 19747887 [TBL] [Abstract][Full Text] [Related]
14. Tobramycin therapy of pulmonary infections in patients with cystic fibrosis. Hawley HB; Lewis RM; Swartz DR; Gump DW Curr Ther Res Clin Exp; 1974 May; 16(5):414-23. PubMed ID: 4209057 [No Abstract] [Full Text] [Related]
15. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Sawicki GS; Signorovitch JE; Zhang J; Latremouille-Viau D; von Wartburg M; Wu EQ; Shi L Pediatr Pulmonol; 2012 Jan; 47(1):44-52. PubMed ID: 21815282 [TBL] [Abstract][Full Text] [Related]
16. Tobramycin inhalation powder (TOBI Podhaler) for the treatment of lung infection in patients with cystic fibrosis. Vazquez-Espinosa E; Marcos C; Alonso T; Giron RM; Gomez-Punter RM; Garcia-Castillo E; Zamora E; Cisneros C; Garcia J; Valenzuela C; Ancochea J Expert Rev Anti Infect Ther; 2016; 14(1):9-17. PubMed ID: 26559549 [TBL] [Abstract][Full Text] [Related]
17. Outpatient treatment of Pseudomonas aeruginosa bronchial colonization with long-term inhaled colistin, tobramycin, or both in adults without cystic fibrosis. Berlana D; Llop JM; Manresa F; Jódar R Pharmacotherapy; 2011 Feb; 31(2):146-57. PubMed ID: 21275493 [TBL] [Abstract][Full Text] [Related]
18. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404 [TBL] [Abstract][Full Text] [Related]
19. Tobramycin inhalation powder (Tobi Podhaler) for cystic fibrosis. Med Lett Drugs Ther; 2013 Jun; 55(1419):51-2. PubMed ID: 23797798 [No Abstract] [Full Text] [Related]
20. [Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in 3 doses in cystic fibrosis]. Canis F; Trivier D; Vic P; Ategbo S; Turck D; Husson MO Pathol Biol (Paris); 1998 Jun; 46(6):449-51. PubMed ID: 9769880 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]